Disease control
Tarceva increased disease control rate (CR PR SD) by 60%. [1,2]
In the overall study population, 60% more patients in the Tarceva arm achieved disease control (CR PR SD) than in the placebo arm (44.0% vs 27.5%). [1,2]
The median duration of disease control was 6.0 months (95% CI=5.7–7.4; n=188) in the Tarceva arm and 4.7 months (95% CI=3.7–5.5; n=58) in the placebo arm (HR=0.53; P=0.0002)[2]
In patients with a response to Tarceva, the median duration of response (CR PR) was 7.9 months (n=38). [1,2]
References
- Tarceva® (erlotinib) summary of product characteristics, F. Hoffmann-La Roche Ltd., 2007.
- Data on file, OSI Pharmaceuticals, Inc.
